D 19466

Known as: D-19466 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2009
01219902009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
  • 2009
Fiebig HH, et al.: Phase I clinical trial of Lobaplatin (D-19466) after intravenous bolus injection. Onkologie 1994;17:142-148… (More)
Is this relevant?
Review
2003
Review
2003
  • Drugs in R&D
  • 2003
Lobaplatin [D 19466] is a platinum complex with DNA alkylating activity that was developed by ASTA Medica (Degussa) for the… (More)
Is this relevant?
Review
2001
Review
2001
Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes containing a 1,2-bis(aminomethyl)cyclobutane stable… (More)
Is this relevant?
1999
1999
The purpose of this study was to determine the influence of impaired renal and liver function on the pharmacokinetics and… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
1996
1996
Lobaplatin consists of two diastereoisomers, LP-D1 and LP-D2. Being a new cytostatic agent it represents platinum compounds of… (More)
Is this relevant?
1995
1995
Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is… (More)
Is this relevant?
1993
1993
A phase I trial with continuous intravenous infusion of lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate… (More)
Is this relevant?
1993
1993
A phase I trial was conducted with lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate) i.v. bolus daily… (More)
  • figure 1
  • table IV
  • table I
  • table II
  • table III
Is this relevant?
1990
1990
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?